Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Paz-Ares, LG; Ciuleanu, TE; Pluzanski, A; Lee, JS; Gainor, JF; Otterson, GA; Audigier-Valette, C; Ready, N; Schenker, M; Linardou, H; Caro, RB; Provencio, M; Zurawski, B; Lee, KH; Kim, SW; Caserta, C; Ramalingam, SS; Spigel, DR; Brahmer, JR; Reck, M; O'Byrne, KJ; Girard, N; Popat, S; Peters, S; Memaj, A; Nathan, F; Aanur, N; Borghaei, H

Paz-Ares, LG (通讯作者)，Univ Complutense Madrid, Hosp Univ 12 Octubre, Med Oncol Dept, Ave Cordoba SN, Madrid 28041, Spain.

JOURNAL OF THORACIC ONCOLOGY, 2023; 18 (1): 79

Abstract

Introduction: We characterized the safety of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large patient population with metastatic NSCLC and e......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索